

Title (en)

Compounds having CRTH2 antagonist activity

Title (de)

Verbindungen mit CRTH2-Antagonisten-Aktivität

Title (fr)

Composés présentant une activité d'antagonistes de CRTH2

Publication

EP 2492268 A1 20120829 (EN)

Application

EP 12168896 A 20070720

Priority

- EP 07766323 A 20070720
- GB 0614608 A 20060722
- GB 0624176 A 20061204

Abstract (en)

Compounds of general formula (1) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

IPC 8 full level

C07D 407/10 (2006.01); **A61K 31/405** (2006.01)

CPC (source: EP KR US)

A61K 9/0019 (2013.01 - KR); **A61K 9/0021** (2013.01 - KR); **A61K 9/006** (2013.01 - KR); **A61K 31/404** (2013.01 - KR); **A61K 31/405** (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/04** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/08** (2017.12 - EP); **A61P 11/14** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 17/14** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 209/10** (2013.01 - KR); **C07D 407/10** (2013.01 - EP KR US)

Citation (applicant)

- EP 0851030 A1 19980701 - BML INC [JP]
- EP 1211513 A1 20020605 - BML INC [JP]
- EP 1170594 A2 20020109 - PFIZER PROD INC [US]
- WO 03066046 A1 20030814 - ASTRAZENECA AB [SE], et al
- WO 03066047 A1 20030814 - ASTRAZENECA AB [SE], et al
- GB 1356834 A 19740619 - ICI LTD
- GB 1407658 A 19750924 - ICI LTD
- GB 1460348 A 19770106 - ICI LTD
- PL 65781 Y1 20120229 - KAWCZYŃSKA KATARZYNA [PL]
- JP 4324418 B2 20090902
- WO 9950268 A2 19991007 - INST FOR PHARM DISCOVERY INC [US], et al
- WO 0032180 A2 20000608 - INST FOR PHARM DISCOVERY INC [US], et al
- WO 0151849 A1 20010719 - KONINKL PHILIPS ELECTRONICS NV [NL]
- WO 0164205 A2 20010907 - INST FOR PHARM DISCOVERY INC [US], et al
- US 4363912 A 19821214 - CROSS PETER E, et al
- WO 9603376 A1 19960208 - LILLY CO ELI [US], et al
- JP 2001247570 A 20010911 - JAPAN TOBACCO INC
- US 4859692 A 19890822 - BERNSTEIN PETER R [US], et al
- US 4273782 A 19810616 - CROSS PETER E, et al
- US 3557142 A 19710119 - BELL MALCOLM R
- WO 03097598 A1 20031127 - SHIONOGI & CO [JP], et al
- EP 0539117 A1 19930428 - LILLY INDUSTRIES LTD [GB]
- US 2003153751 A1 20030814 - SEEHRA JASBIR S [US], et al
- US 2004011648 A1 20040122 - PAUL PHILLIP H [US], et al
- WO 2004058164 A2 20040715 - TULARIK INC [US]
- WO 03097042 A1 20031127 - SHIONOGI & CO [JP], et al
- WO 03101981 A1 20031211 - ASTRAZENECA AB [SE], et al
- WO 03101961 A1 20031211 - ASTRAZENECA AB [SE], et al
- WO 2004007451 A1 20040122 - ASTRAZENECA AB [SE], et al
- WO 2005019171 A1 20050303 - ASTRAZENECA AB [SE], et al
- WO 2005094816 A1 20051013 - ACTELION PHARMACEUTICALS LTD [CH], et al
- WO 2006034419 A2 20060330 - ATHERSYS INC [US], et al
- WO 2005044260 A1 20050519 - OXAGEN LTD [GB], et al
- MURRAY, N. ENGL. J. MED., vol. 315, 1986, pages 800 - 804
- HARDY ET AL., N. ENGL. J. MED., vol. 311, 1984, pages 209 - 213
- SAMPSON ET AL., THORAX, vol. 52, 1997, pages 513 - 518
- EMERY ET AL., J. APPL. PHYSIOL., vol. 67, 1989, pages 959 - 962
- FUJITANI ET AL., J. IMMUNOL., vol. 168, 2002, pages 443 - 449
- HIRAI ET AL., J. EXP. MED., vol. 193, 2001, pages 255 - 261
- MONNERET ET AL., J. PHARNIACOL. EXP. THER., vol. 304, 2003, pages 349 - 355
- GERVAIS ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 108, 2001, pages 982 - 988
- J. MED. CHEM., vol. 6, no. 33, 1990, pages 1781 - 1790
- CROSS ET AL., J. MED. CHEM., vol. 29, 1986, pages 342 - 346

Citation (search report)

- [AD] WO 2005044260 A1 20050519 - OXAGEN LTD [GB], et al
- [A] US 5641800 A 19970624 - BACH NICHOLAS J [US], et al
- [A] EP 1505061 A1 20050209 - SHIONOGI & CO [JP]

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

WO 2008012511 A1 20080131; AU 2007279079 A1 20080131; BR PI0714840 A2 20130521; CA 2658496 A1 20080131; CY 1114141 T1 20160727; DK 2046740 T3 20120820; EP 2046740 A1 20090415; EP 2046740 B1 20120523; EP 2492268 A1 20120829; ES 2391671 T3 20121128; HK 1130256 A1 20091224; IL 196640 A0 20091118; IL 196640 A 20130131; JP 2010500966 A 20100114; JP 5270542 B2 20130821; KR 20090042808 A 20090430; MX 2009000801 A 20090203; NO 20090216 L 20090312; NZ 574375 A 20110630; PL 2046740 T3 20121031; PT 2046740 E 20120828; RU 2009101297 A 20100827; RU 2458918 C2 20120820; SI 2046740 T1 20121231; US 2010035956 A1 20100211; US 2011268693 A1 20111103; US 7999119 B2 20110816; US 8268878 B2 20120918

DOCDB simple family (application)

GB 2007002761 W 20070720; AU 2007279079 A 20070720; BR PI0714840 A 20070720; CA 2658496 A 20070720; CY 121100744 T 20120820; DK 07766323 T 20070720; EP 07766323 A 20070720; EP 12168896 A 20070720; ES 07766323 T 20070720; HK 09109239 A 20091006; IL 19664009 A 20090121; JP 2009520057 A 20070720; KR 20097003615 A 20090223; MX 2009000801 A 20070720; NO 20090216 A 20090114; NZ 57437507 A 20070720; PL 07766323 T 20070720; PT 07766323 T 20070720; RU 2009101297 A 20070720; SI 200730995 T 20070720; US 201113180157 A 20110711; US 37470207 A 20070720